Treatment of non-alcoholic fatty liver disease

摘要: Non-alcoholic fatty liver disease, defined as the presence of macrovascular steatosis in less than 20 gm alcohol ingestion per day, is most common disease USA. It commonly associated with insulin resistance/type 2 diabetes mellitus and obesity. manifested by steatosis, steatohepatitis, cirrhosis, and, rarely, hepatocellular carcinoma. Hepatic results from an imbalance between uptake fat its oxidation export. Insulin resistance, predisposing to lipolysis peripheral mobilization acids liver, consistent underlying pathogenic factor. not known why some patients progress cirrhosis; however, induction CYP 2E1 generation reactive oxygen species appears be important. Treatment directed at weight loss plus pharmacologic therapy targeted toward resistance or dyslipidemia. Bariatric surgery has proved effective. While no been approved, emerging data on thiazolidinediones have demonstrated improvement both enzymes histology. There are fewer, but promising data, statins which shown hepatoprotective other diseases. The initial enthusiasm for ursodeoxycholic acid supported histologic studies.